Radiation and immunotherapy for advanced liver cancer before transplant
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining radiation therapy with immunotherapy (AtezoBev) before a liver transplant for advanced liver cancer. The goal is to see if this approach can shrink tumors and make transplant possible for more people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You weigh more than 30 kg (about 66 pounds)
- Your liver function is fairly good (Child-Pugh score A5 to B7)
- The cancer has spread into nearby blood vessels (but not the main portal vein)
- The total tumor size is less than 350 cubic centimeters (about the size of a small grapefruit)
- You have no cancer spread outside the liver
- Your cancer is confirmed by imaging or biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a combination of immunotherapy (atezolizumab), targeted therapy (bevacizumab), and targeted radiation for advanced liver cancer that cannot be surgically removed. The goal is to see if this approach helps control the cancer.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests giving atezolizumab plus bevacizumab before liver transplant in people with hepatocellular carcinoma (HCC) that is too advanced to be listed within the “Milan criteria,” but still transplant-eligible. The goal is to control the cancer outside the transplant period and improve transplant outcomes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.